From New Molecular Insights to New Treatment Options in Endometrial Cancer
Endometrial cancer remains the most common gynecological cancer in Europe and the US, with excellent survival rates in patients with early-stage disease.^1^ However, the prognosis of advanced/metastatic endometrial cancer is dismal. There is a considerable need to refine treatment options in the adj...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2022-03-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000//hbT.OH.2022.11.063 |
| _version_ | 1797246867070779392 |
|---|---|
| author | Ursula Hasler-Strub |
| author_facet | Ursula Hasler-Strub |
| author_sort | Ursula Hasler-Strub |
| collection | DOAJ |
| description | Endometrial cancer remains the most common gynecological cancer in Europe and the US, with excellent survival rates in patients with early-stage disease.^1^ However, the prognosis of advanced/metastatic endometrial cancer is dismal. There is a considerable need to refine treatment options in the adjuvant and metastatic settings, especially after the failure of first-line platinum-based chemotherapy. Nowadays, immune checkpoint inhibitors (ICIs) have the potential to change the systemic treatment landscape of endometrial cancer. |
| first_indexed | 2024-04-24T19:49:37Z |
| format | Article |
| id | doaj.art-83551da8fead43b6a64d52acce0865a2 |
| institution | Directory Open Access Journal |
| issn | 2673-2092 2673-2106 |
| language | English |
| last_indexed | 2024-04-24T19:49:37Z |
| publishDate | 2022-03-01 |
| publisher | THE HEALTHBOOK COMPANY LTD. |
| record_format | Article |
| series | healthbook TIMES. Oncology Hematology |
| spelling | doaj.art-83551da8fead43b6a64d52acce0865a22024-03-24T18:33:51ZengTHE HEALTHBOOK COMPANY LTD.healthbook TIMES. Oncology Hematology2673-20922673-21062022-03-01111From New Molecular Insights to New Treatment Options in Endometrial CancerUrsula Hasler-StrubEndometrial cancer remains the most common gynecological cancer in Europe and the US, with excellent survival rates in patients with early-stage disease.^1^ However, the prognosis of advanced/metastatic endometrial cancer is dismal. There is a considerable need to refine treatment options in the adjuvant and metastatic settings, especially after the failure of first-line platinum-based chemotherapy. Nowadays, immune checkpoint inhibitors (ICIs) have the potential to change the systemic treatment landscape of endometrial cancer.https://doi.org/10.36000//hbT.OH.2022.11.063 |
| spellingShingle | Ursula Hasler-Strub From New Molecular Insights to New Treatment Options in Endometrial Cancer healthbook TIMES. Oncology Hematology |
| title | From New Molecular Insights to New Treatment Options in Endometrial Cancer |
| title_full | From New Molecular Insights to New Treatment Options in Endometrial Cancer |
| title_fullStr | From New Molecular Insights to New Treatment Options in Endometrial Cancer |
| title_full_unstemmed | From New Molecular Insights to New Treatment Options in Endometrial Cancer |
| title_short | From New Molecular Insights to New Treatment Options in Endometrial Cancer |
| title_sort | from new molecular insights to new treatment options in endometrial cancer |
| url | https://doi.org/10.36000//hbT.OH.2022.11.063 |
| work_keys_str_mv | AT ursulahaslerstrub fromnewmolecularinsightstonewtreatmentoptionsinendometrialcancer |